Sanofi & Owkin Expand AI Drug Discovery with K Pro

Sanofi and Owkin are expanding their AI collaboration with a new initiative. This builds on a relationship that started in 2021. Here's the thing: Owkin will develop AI-driven biopharma agents specifically for Sanofi. These agents will be deployed through Owkin's AI Scientist platform, K Pro, which combines patient data with biological AI systems. This new agreement also includes a five-year license for K Pro. What's interesting is their initial partnership focused on oncology and patient analysis, later expanding to Sanofi's immunology pipeline. This deeper integration of AI aims to enhance the discovery and development of new medicines. Owkin seeks to achieve Biological Artificial Superintelligence to automate complex R&D challenges. The bottom line: This collaboration could lead to faster and more confident decision-making in drug development.